Page 5 - Patrickr Oneil News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrickr oneil. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrickr Oneil Today - Breaking & Trending Today

Patrick R. O'neil Sells 1,527 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) EVP Patrick R. O’neil sold 1,527 shares of the company’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $41.70, for a total transaction of $63,675.90. Following the sale, the executive vice president now directly owns 40,355 shares in the […] ....

Patrickr Oneil , Ionis Pharmaceuticals Company Profile , Ionis Pharmaceuticals , Ionis Pharmaceuticals Inc , Securities Exchange Commission , Institutional Investors Weigh In On Ionis Pharmaceuticals , Royal Bank , Vanguard Group Inc , Morgan Stanley , Ionis Pharmaceuticals Trading Down , News Ratings For Ionis Pharmaceuticals Daily , T Rowe Price Investment Management Inc , Clearbridge Investments , Quarter For Ionis Pharmaceuticals , Tweedy Browne Co , Get Rating , Exchange Commission , Pharmaceuticals Trading Down , Rowe Price Investment Management , Ionis Core , Ionis Pharmaceuticals Daily , Nasdaq Ions , Insider Trading , Nsider Trades ,

Zacks Research Comments on Ionis Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) – Stock analysts at Zacks Research increased their Q1 2023 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 19th. Zacks Research analyst K. Shah now forecasts that the company will earn ($1.00) per share […] ....

Patrickr Oneil , Piper Sandler , Dekabank Deutsche Girozentrale , Ionis Pharmaceuticals Inc , Zacks Research , Securities Exchange Commission , Morgan Stanley , Ionis Pharmaceuticals Company Profile , Ionis Pharmaceuticals , Ionis Pharmaceuticals Trading , News Ratings For Ionis Pharmaceuticals Daily , Algert Global , Tower Research Capital , Gateway Investment Advisers , Royal Bank , Get Rating , Ionis Pharmaceutical , Research Capital , Investment Advisers , Bank Deutsche Girozentrale , Exchange Commission , Ionis Core , Ionis Pharmaceuticals Daily , Nasdaq Ions , Earnings Estimates ,

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 23.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 336,732 shares of the company’s stock after selling 100,444 shares during the period. Sumitomo Mitsui […] ....

Piper Sandler , Patrickr Oneil , Ionis Pharmaceuticals Inc , Quarter For Ionis Pharmaceuticals , Ionis Pharmaceuticals , Ionis Pharmaceuticals Trading Down , Securities Exchange Commission , Almanack Investment Partners , Needham Company , Exchange Commission , Wipfli Financial Advisors , Guardian Wealth Advisors , Sumitomo Mitsui Trust Holdings Inc , Ionis Pharmaceuticals Profile , News Ratings For Ionis Pharmaceuticals Daily , Sumitomo Mitsui Trust Holdings , Get Rating , Mitsui Trust Holdings , Financial Advisors , Wealth Advisors , Investment Partners , Quantbot Technologies , Pharmaceuticals Trading Down , Ionis Core , Ionis Pharmaceuticals Daily , Nasdaq Ions ,

AtonRa Partners Decreases Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

AtonRa Partners reduced its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 21.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,875 shares of the company’s stock after selling 3,753 shares during the period. AtonRa Partners’ holdings in […] ....

Eric Swayze , Piper Sandler , Patrickr Oneil , Algert Global , Ionis Pharmaceuticals , Royal Bank , Quarter For Ionis Pharmaceuticals , Ionis Pharmaceuticals Price Performance , Exchange Commission , Morgan Stanley , News Ratings For Ionis Pharmaceuticals Daily , Gateway Investment Advisers , Ionis Pharmaceuticals Company Profile , Ionis Pharmaceuticals Inc , Tower Research Capital , Atonra Partners , Get Rating , Research Capital , Investment Advisers , Brookstone Capital Management , Capital Management , Ionis Core , Visit Holdingschannel , Ionis Pharmaceuticals Daily , Nasdaq Ions , Sec Filings ,

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Hold" by Brokerages

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) has received a consensus rating of “Hold” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating on the company. The average […] ....

United States , Patrickr Oneil , Eric Swayze , Morgan Stanley , Institutional Trading Of Ionis Pharmaceuticals , Ionis Pharmaceuticals Inc , Ionis Pharmaceuticals Trading , News Ratings For Ionis Pharmaceuticals Daily , Securities Exchange Commission , Delphia United States Inc , Lincoln National Corp , Needham Company , Commerce Bank , Ionis Pharmaceuticals Company Profile , Ionis Pharmaceuticals , Analyst Recommendations For Ionis Pharmaceuticals , Get Rating , Exchange Commission , Financial Advisors , National Corp , Ionis Core , Akcea Therapeutics , Ionis Pharmaceuticals Daily , Nasdaq Ions ,